Citadel Advisors’s Endovia Health Sciences, Inc. EDVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-49
Closed -$1.26K 15431
2024
Q4
$1.26K Sell
49
-134
-73% -$4.44K ﹤0.01% 14209
2024
Q3
$7.36K Buy
183
+63
+53% +$3.17K ﹤0.01% 13366
2024
Q2
$4.42K Buy
120
+7
+6% +$328 ﹤0.01% 13486
2024
Q1
$8.33K Buy
113
+33
+41% +$2.63K ﹤0.01% 13564
2023
Q4
$7.07K Sell
80
-19
-19% -$1.81K ﹤0.01% 13315
2023
Q3
$9.38K Buy
99
+39
+65% +$5.05K ﹤0.01% 13131
2023
Q2
$10.8K Sell
60
-46
-43% -$8.41K ﹤0.01% 13181
2023
Q1
$27.9K Buy
106
+47
+80% +$9.31K ﹤0.01% 12801
2022
Q4
$9.13K Sell
59
-13
-18% -$2.28K ﹤0.01% 13704
2022
Q3
$16K Sell
72
-1,718
-96% -$652K ﹤0.01% 12149
2022
Q2
$856K Sell
1,790
-308
-15% -$111K ﹤0.01% 7380
2022
Q1
$953K Buy
+2,098
New +$1.07M ﹤0.01% 7816

Other funds holding EDVA

Citadel Advisors's EDVA Position: Q2 2026 in Review

Citadel Advisors sold out of Endovia Health Sciences, Inc. (EDVA) in Q2 2026, closing a stake of 4,146 shares — an estimated $5.96K sold.

Citadel Advisors first reported a position in EDVA in Q2 2022 and held it in 10 quarters. The position peaked at $206K in Q4 2022. 18 funds tracked by Wall St. Rank hold EDVA as of Q2 2026.

  • Citadel Advisors reported no remaining Endovia Health Sciences, Inc. position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 4,146 Endovia Health Sciences, Inc. shares in Q2 2026, an estimated $5.96K.
  • Citadel Advisors first reported a position in Endovia Health Sciences, Inc. in Q2 2022 and held it in 10 quarters.
  • Citadel Advisors's Endovia Health Sciences, Inc. position peaked at $206K in Q4 2022.
  • 18 funds tracked by Wall St. Rank held Endovia Health Sciences, Inc. as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.